Skip to main content
Premium Trial:

Request an Annual Quote

Multiomics Biosensing Startup Pleno Closes $40M Series A Round

NEW YORK – Biosensing startup Pleno said Wednesday that it has closed a $40 million Series A funding round.

The round was led by Deerfield Management with participation from Foresite Capital. San Diego-based Pleno said it will use the funds to accelerate development of its Raptor instrument platform, which uses the firm's Hypercoding technology. It combines barcoded DNA and signal processing to enable highly plexed, high-throughput detection of nucleic acids.

According to Pleno, the Raptor system will be capable of detecting up to 10,000 nucleic acid targets per sample and processing up to 10,000 samples per day. It will offer a more streamlined, less expensive, and higher-throughput alternative to next-generation sequencing in applications looking to analyze large numbers of known nucleic acid targets.

The platform will also enable analysis of other kinds of analytes, such as proteins.

The company is planning an early-access launch of the platform in 2023 and a broad commercial launch in 2024.

The Series A round follows $15 million in pre-Series A funding the company announced in May.

"Deerfield is proud to lead Pleno’s Series A financing,” Andrew ElBardissi, a partner at Deerfield Management, said in a statement. "Pleno’s team has developed a versatile platform at the intersection of technology and life sciences which has the potential to disrupt existing sequencing and multiomic approaches that are critical for drug development and clinical diagnostics."

"The overwhelming interest already received from potential customers has clearly shown just how important this technology is and how much it is needed across a wide variety of applications, ranging from early cancer screening, NIPT, and infectious diseases, to pharmacogenomics, proteomics, and agrigenomics," Pieter van Rooyen, Pleno's founder and CEO, added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.